Q-omics provides the consensus-scored FBXO7 profile across patient tissues and cancer cell-line models. FBXO7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXO7 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FBXO7 protein abundance shows 19,432 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, HNSC, and CCRCC as cancer lineages where FBXO7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO7 survival associations across molecular data types. FBXO7 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO7 RNA expression–survival associations across cancer types. High FBXO7 expression shows unfavorable associations in ACC and HNSC, but favorable associations in KIRC, UVM, READ and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXO7 RNA expression.
This table summarizes FBXO7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXO7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO7 shows lower tumor expression in THCA, LUAD, KIRP, LUSC and UCEC and higher tumor expression in HNSC. The HNSC box plot shows higher FBXO7 RNA expression in tumor versus normal tissue (log2 FC = +0.835, t-test p < 0.001).
This table shows molecular features associated with FBXO7 in patient tissues and cancer cell lines. In patient samples, FBXO7 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
